Real-World, Observational, Retrospective Study to Evaluate the Effectiveness and Safety of Treatment with Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Background: Hepatocellular carcinoma (HCC) accounts for approximately 90% of liver cancer cases. Sorafenib, the first drug to demonstrate survival benefits for advanced HCC, was validated through the SHARP randomized clinical trial (RCT). While RCTs are essential for assessing new therapies, real-wo...

Full description

Saved in:
Bibliographic Details
Main Authors: Angélica Richart Csipak, Leonardo G. da Fonseca, Rossana Verónica Mendoza López, Maria Del Pilar Estevez-Diz
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Current Oncology
Subjects:
Online Access:https://www.mdpi.com/1718-7729/31/11/500
Tags: Add Tag
No Tags, Be the first to tag this record!